NCT06487403View on ClinicalTrials.gov

HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2028

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
RADIATION

Standard of care external beam radiotherapy (single integrated boost)

70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.

RADIATION

Standard of care external beam radiotherapy (two-phase treatment)

70Gy in 35 fractions, delayed 40 Gy in 20 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER